Evidence map›Paper›PMID 35691738›Full record

ArticleAnais brasileiros de dermatologia

Rhino-orbito-cerebral mucormycosis caused by Rhizopus microsporus var. microsporus in a diabetic patient with COVID-19.

Sandy Daniele Munhoz, Rute Facchini Lellis, Ana Paula Carvalho Reis, Gilda Maria Barbaro Del Negro, Maria Glória Teixeira Sousa, John Verrinder Veasey

Open access · goldAbstract readCase Reports
In one paragraph

Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Pattern-based clinical recognition of diabetes-associatedFrontiers in cellular and infection microbiology · 2026
    Review
  2. Fatal Pharyngeal Cellulitis Caused byInfection and drug resistance · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sandy Daniele MunhozDermatology Clinic, Hospital da Santa Casa de São Paulo, São Paulo, SP, Brazil.
Rute Facchini LellisPathology Laboratory, Hospital da Santa Casa de São Paulo, São Paulo, SP, Brazil.
Ana Paula Carvalho ReisMedical Mycology Laboratory ‒ LIM-53, Division of Clinical Dermatology, Faculty of Medicine, Hospital das Clínicas and Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, Brazil.
Gilda Maria Barbaro Del NegroMedical Mycology Laboratory ‒ LIM-53, Division of Clinical Dermatology, Faculty of Medicine, Hospital das Clínicas and Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, Brazil.
Maria Glória Teixeira SousaMedical Mycology Laboratory ‒ LIM-53, Division of Clinical Dermatology, Faculty of Medicine, Hospital das Clínicas and Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, Brazil.
John Verrinder VeaseyDermatology Clinic, Hospital da Santa Casa de São Paulo, São Paulo, SP, Brazil; Medical Sciences College, Santa Casa de São Paulo, São Paulo, SP, Brazil. Electronic address: johnveasey@uol.com.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRSanta Casa Hospital · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 disease caused by the SARS-CoV-2 coronavirus causes a wide range of clinical manifestations, ranging from mild to severe, with the main ones affecting the respiratory tract, such as pneumonia. In patients with greater severity, the high frequency of bacterial and fungal coinfection stands out, a situation related both to the patient's pre-existing comorbidities and due to the hospitalization itself. Cases of mucormycosis associated with COVID-19 were highlighted in the lay and scientific media, with the increase in mycosis cases being directly and indirectly attributed to the viral infection. This report describes a case of rhino-orbito-cerebral mucormycosis in a diabetic patient hospitalized for COVID-19, whose diagnosis was confirmed by identifying the agent Rhizopus microsporus var. microsporus through culture for fungi and PCR examination.

Indexed as

COVID-19Diabetes MellitusMucormycosisAntifungal AgentsHumansRhizopusSARS-CoV-2Antifungal AgentsAmphotericin BCoronavirusCOVID-19Diabetes mellitusDiagnosisMucormycosis

Identifiers

PMID35691738
PMCPMC9181896
OpenAlexW4281668954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.